DIG
CGTX icon

Dauntless Investment Group’s Cognition Therapeutics CGTX Stock Holding History

Dauntless Investment Group’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427K Sell
371,701
-59,299
-14% -$70.2K 0.34% 39
2026
Q1 		$327K Sell
431,000
-35,000
-8% -$40.7K 0.22% 39
2025
Q4 		$629K Buy
+466,000
New +$756K 0.5% 30

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.47B AUM 18.73% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Dauntless Investment Group's CGTX Position: Q2 2026 in Review

Dauntless Investment Group reduced its Cognition Therapeutics (CGTX) stake by 14% in Q2 2026, selling an estimated $70.2K and leaving 371,701 shares worth $427K. The position accounts for 0.34% of the portfolio, ranked #39.

Dauntless Investment Group first reported a position in CGTX in Q4 2025 and has held it in 3 quarters since. The position peaked at $629K in Q4 2025. 66 funds tracked by Wall St. Rank hold CGTX as of Q2 2026.

  • Dauntless Investment Group held 371,701 shares of Cognition Therapeutics worth $427K as of Q2 2026.
  • Dauntless Investment Group sold 59,299 Cognition Therapeutics shares in Q2 2026, an estimated $70.2K.
  • Cognition Therapeutics made up 0.34% of Dauntless Investment Group's portfolio in Q2 2026, its #39 holding.
  • Dauntless Investment Group first reported a position in Cognition Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Dauntless Investment Group's Cognition Therapeutics position peaked at $629K in Q4 2025.
  • 66 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q2 2026.

Based on Dauntless Investment Group's 13F filing for Q2 2026, filed 13 Aug 2026.